KRC Kilroy Realty Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 53
Relative Valuation: Rel. Valuation: 59
Relative Profitability: Rel. Profitability: 62

EPS in 2026 (TTM): $1.85

Last Report Period Date: Mar 31, 2026

Currently, KRC's 12-month EPS stands at $1.85, according to the most recent financial reports. During 2025, KRC reported a per-share earnings of $2.33, which shows a rise compared to the EPS of $1.78 recorded in 2024. KRC recorded an EPS of -$0.16 for the quarterly period ending on Mar 31, 2026.

KRC earnings history

Historical annual and quarterly earnings per share (EPS) data for Kilroy Realty
EPS (TTM)
$1.85
EPS Growth YoY (Quarterly)
-148.5%
EPS (Quarterly)
-$0.16
EPS Growth (Quarterly)
-245.5%

In 2025, Kilroy Realty's earnings per share was $2.33, a rise of 30.9% from $1.78 in 2024. Over the quarter ending Mar 31, 2026, the earnings per share came in at -$0.16, reflecting a 148.5% decline compared to the same quarter a year earlier. As of March 2026, the TTM EPS is $1.85. During 2024, the annual earnings per share was $1.78, representing a decrease of 1.1% compared to 2023.

KRC earnings chart

KRC EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-148.5%
EPS growth YoY
30.9%
EPS growth 3Y avg
5.6%
EPS growth 5Y avg
7.4%

In the past 12 months, Kilroy Realty has recorded an earnings per share growth rate of -148.5% (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of 5.6% per year. In the last five years, the company had an average annual EPS growth of 7.4%. When assessed over a ten-year period, KRC's average EPS annual growth was -0.5%.

KRC Earnings Waterfall

Breakdown of revenue, profit and net income for Kilroy Realty

KRC Earnings vs Peers

What are the earnings of KRC compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
INTU Intuit Inc 15.58 30.6% 23.3% 14.6%
KRC Kilroy Realty Corp 20.11 30.9% 5.6% 7.4%
MSFT Microsoft Corp 22.18 15.5% 12.2% 18.7%
NBIX Neurocrine Biosciences Inc 24.06 41.5% 44% 1.9%

All data is based on quarterly TTM periods, unless otherwise specified.